In this issue:
Drug survival of biologics in psoriasis
Bimekizumab in hidradenitis suppurativa
Dupilumab in hepatic pruritus
Omalizumab dose escalation and BMI
Biologic vs JAK inhibitor initiation in atopic dermatitis
Dupilumab and haematologic malignancy
Nemolizumab cutaneous adverse events
Dupilumab drug survival in atopic dermatitis
IL-17 inhibitors in special site psoriasis
Biologic perceptions and undertreatment
Please login below to download this issue (PDF)